Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Bharat Biotech’s oral cholera vaccine, Hillchol, aims to ease a critical global shortfall, with the world currently lacking ...

Study findings have been published in the Science Direct, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and l ...

A Massachusetts-based wound care and sports medicine company announced plans for its brand-new biomanufacturing facility ...

Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...

FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...